Vedana Therapeutics is a Seattle biotechnology company developing next-generation antibody therapies for migraine prevention.
Vedana Therapeutics has raised $46.0M in total funding. The most recent round was Series A. The last funding was announced in June 2026.
Vedana Therapeutics's investors include Canaan Partners, Westlake Village BioPartners, Alexandria Venture Investments, Dawn Biopharma.
Vedana Therapeutics is headquartered in Seattle, United States.
Vedana Therapeutics is a Seattle biotechnology company developing next-generation antibody therapies for migraine prevention.
Vedana Therapeutics is at the Series A stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Vedana Therapeutics — Funding & Investors." VCBacked, June 17, 2026, https://www.vcbacked.co/company/vedana-therapeutics. Accessed September 30, 2026.
VCBacked. (2026). Vedana Therapeutics — Funding & Investors. Retrieved September 30, 2026, from https://www.vcbacked.co/company/vedana-therapeutics
{{cite web |title=Vedana Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/vedana-therapeutics |website=VCBacked |access-date=September 30, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated